The principal investigator reported at the ASGCT meeting that the study met its primary endpoint, though there were two treatment-related serious adverse events.

On CGTxchange, sponsors can list their shelved cell and gene therapies in the hopes that other investors, partners, and ...

The latest decision makes these treatments routinely available after having been accessible only through a managed access scheme.

Sponsor Benitec anticipates formalizing its plan for a pivotal trial of BB-301 with the US Food and Drug Administration in mid-2026.

The agency approved the antibody-drug conjugate for treating HER2-positive neoadjuvant and adjuvant breast cancer alongside an IHC and an ISH test for identifying best responders.

The firm said the preclinical data supports studying its lead candidate SIL-204 in combination with immunotherapy in KRAS-mutant pancreatic cancer.

The ex vivo therapies from BRL Medicine and Reforgene Medicine use different strategies to boost production of fetal ...

The CELIA trial didn't meet its main goal of assessing dose response for change from baseline on a clinical dementia scale, but the ASO diranersen did lower tau levels and slow clinical decline.

Even though Arvinas and Pfizer appear to have "written off" the drug, in one analyst's view, Rigel believes it can drive adoption among community-treated patients lacking SERD access.

Regeneron's Otarmeni was recently FDA approved for patients with OTOF-related hearing loss based on CHORD trial results.

The partners will incorporate Telix's PSMA-PET gallium 68-based imaging agents Gozellix and Illuccix with EDAP and Profound's technologies for minimally invasive treatment.